Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer

Table 6 Analysis of metastatic patterns among patients with single organ-only metastasis (N = 113) ^a

Initial metastatic or recurred site	WT KRAS	MT KRAS	Total N^a	P-value
	N (%)	N (%)
Liver				< 0.001
Yes	34 (65.4)	17 (27.9)	51
No	18 (34.6)	44 (72.1)	62
Lung				< 0.001
Yes	6 (11.5)	25 (41.0)	31
No	46 (88.5)	36 (59.0)	82
Distant lymph nodes				0.411
Yes	4 (7.7)	2 (3.3)	6
No	48 (92.3)	59 (96.7)	107
Peritoneum^b				0.062
Yes	7 (13.5)	17 (27.9)	24
No	45 (86.5)	44 (72.1)	89

^a The association between initial metastatic or recurred sites and KRAS status was analyzed in patients with metastasis confined to a single organ at the time of diagnosis of MRCRC (N = 113; 30 patients with initial systemic metastasis involving ≥ 2 organs simultaneously at the time of diagnosis of MRCRC were excluded).
^b Of 24 patients, cases with simultaneous peritoneal and ovarian metastases (N = 6) were included; there were no cases with ovarian metastasis alone without peritoneal metastasis in our study. When patients with peritoneal metastasis only without Krukenberg tumor (N = 107) were separately analyzed, the result was not different [WT KRAS 10.0% (5/50) vs. MT KRAS 22.8% (13/57); P = 0.077].
Abbreviations: WT, wild-type; MT, mutant-type; MRCRC, metastatic or recurrent colorectal cancer.

ISSN: 1471-2407